CN101589026B - 治疗脑神经胶质瘤的方法 - Google Patents

治疗脑神经胶质瘤的方法 Download PDF

Info

Publication number
CN101589026B
CN101589026B CN2007800311672A CN200780031167A CN101589026B CN 101589026 B CN101589026 B CN 101589026B CN 2007800311672 A CN2007800311672 A CN 2007800311672A CN 200780031167 A CN200780031167 A CN 200780031167A CN 101589026 B CN101589026 B CN 101589026B
Authority
CN
China
Prior art keywords
optional substituted
compound
alkyl
purposes
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800311672A
Other languages
English (en)
Chinese (zh)
Other versions
CN101589026A (zh
Inventor
阿什利·布什
佩内罗普·J·哈金斯
杰克·G·帕森斯
盖克·B·科克
维加亚·肯克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alterity Therapeutics Ltd
Original Assignee
Prana Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prana Biotechnology Ltd filed Critical Prana Biotechnology Ltd
Publication of CN101589026A publication Critical patent/CN101589026A/zh
Application granted granted Critical
Publication of CN101589026B publication Critical patent/CN101589026B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2007800311672A 2006-06-22 2007-06-22 治疗脑神经胶质瘤的方法 Expired - Fee Related CN101589026B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81577906P 2006-06-22 2006-06-22
US60/815,779 2006-06-22
PCT/AU2007/000876 WO2007147217A1 (en) 2006-06-22 2007-06-22 Method of treatment of glioma brain tumour

Publications (2)

Publication Number Publication Date
CN101589026A CN101589026A (zh) 2009-11-25
CN101589026B true CN101589026B (zh) 2013-10-16

Family

ID=38833006

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800311672A Expired - Fee Related CN101589026B (zh) 2006-06-22 2007-06-22 治疗脑神经胶质瘤的方法

Country Status (9)

Country Link
US (1) US8163760B2 (https=)
EP (1) EP2044026B1 (https=)
JP (1) JP5415942B2 (https=)
CN (1) CN101589026B (https=)
AU (1) AU2007262670B2 (https=)
CA (1) CA2656825C (https=)
DK (1) DK2044026T3 (https=)
ES (1) ES2474865T3 (https=)
WO (1) WO2007147217A1 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
CN101534826A (zh) * 2006-04-14 2009-09-16 普拉纳生物技术有限公司 治疗与年龄相关的黄斑变性（amd）的方法
US8163779B2 (en) * 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US9321730B2 (en) * 2007-08-21 2016-04-26 The Hong Kong Polytechnic University Method of making and administering quinoline derivatives as anti-cancer agents
SG187502A1 (en) 2008-02-01 2013-02-28 Takeda Pharmaceutical Oxim derivatives as hsp90 inhibitors
GB0806794D0 (en) * 2008-04-15 2008-05-14 Ludwig Inst Cancer Res Therapeutic compounds
AU2009282480B2 (en) * 2008-08-11 2015-05-07 Children's Medical Center Corporation Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
WO2010071944A1 (en) * 2008-12-24 2010-07-01 Prana Biotechnology Limited Quinazolinone compounds
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
WO2012083866A1 (en) * 2010-12-22 2012-06-28 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
FR2984317B1 (fr) * 2011-12-20 2015-02-27 Univ Rennes Composes chelateurs de metal presentant au moins une chaine polyaminee.
US10155742B2 (en) 2012-01-13 2018-12-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR101685862B1 (ko) 2012-12-27 2016-12-20 에프. 호프만-라 로슈 아게 Comt 억제제
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US10005739B2 (en) 2013-10-23 2018-06-26 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2968090A1 (en) * 2014-12-02 2016-06-09 Prana Biotechnology Limited 4h-pyrido[1,2-a]pyrimidin-4-one compounds
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP7402792B2 (ja) * 2017-09-26 2023-12-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
EP3801525A4 (en) 2018-06-08 2022-03-23 The General Hospital Corporation PROLYL TRNA SYNTHETASE INHIBITORS
EP3870179A4 (en) 2018-10-22 2022-11-23 Dana Farber Cancer Institute, Inc. USP7 ESCAPEMENT
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
CN111471012B (zh) * 2019-01-23 2023-04-25 鲁南制药集团股份有限公司 一种蜈蚣喹啉类化合物、制备方法及其应用
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN110240590B (zh) * 2019-07-16 2025-09-19 广州新民培林医药科技有限公司 一类嘧啶喹啉衍生物及其制备方法和应用
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN115151540A (zh) 2019-12-02 2022-10-04 风暴治疗有限公司 作为mettl3抑制剂的多杂环化合物
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CN113214249B (zh) * 2021-04-23 2023-09-19 成都大学 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
PT4426434T (pt) 2021-11-02 2025-11-24 Flare Therapeutics Inc Agonistas inversos de pparg e suas utilizações
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
CN116410132B (zh) * 2023-02-23 2024-07-09 广东工业大学 一种8-羟基喹啉类化合物及其制备方法和在制备抗肿瘤药物上的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1654A (en) 1999-03-24 2006-09-01 Anormed Inc Chemokine receptor binding heterocyclic compounds.
CN1891693A (zh) * 2000-01-24 2007-01-10 基纳西亚股份有限公司 用于治疗的吗啉代基取代的化合物
AU2002230056A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Indole derivatives and their uses as heparanase inhibitors
JP2005504014A (ja) * 2001-06-08 2005-02-10 サイトビア インコーポレイテッド カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された３−アリール−５−アリール−［１，２，４］−オキサジアゾール類および類似体、並びにその使用法
WO2003072578A1 (en) 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
AU2003282726B2 (en) * 2002-10-03 2010-10-07 Targegen, Inc. Vasculostatic agents and methods of use thereof
JP4690043B2 (ja) * 2002-10-04 2011-06-01 プラナ バイオテクノロジー リミティッド 神経に対し活性な化合物
WO2005063213A1 (en) * 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
US20060100226A1 (en) * 2004-09-10 2006-05-11 Sikorski James A 2-Thiopyrimidinones as therapeutic agents
KR20080080584A (ko) * 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
DE102005059479A1 (de) 2005-12-13 2007-06-14 Merck Patent Gmbh Hydroxychinolinderivate
CN101534826A (zh) * 2006-04-14 2009-09-16 普拉纳生物技术有限公司 治疗与年龄相关的黄斑变性（amd）的方法

Also Published As

Publication number Publication date
CA2656825A1 (en) 2007-12-27
US20100069393A1 (en) 2010-03-18
EP2044026B1 (en) 2014-03-26
AU2007262670B2 (en) 2012-12-20
CN101589026A (zh) 2009-11-25
WO2007147217A1 (en) 2007-12-27
JP2009541223A (ja) 2009-11-26
EP2044026A1 (en) 2009-04-08
ES2474865T3 (es) 2014-07-09
CA2656825C (en) 2013-12-10
AU2007262670A2 (en) 2009-03-26
DK2044026T3 (da) 2014-06-30
AU2007262670A1 (en) 2007-12-27
JP5415942B2 (ja) 2014-02-12
EP2044026A4 (en) 2009-08-05
US8163760B2 (en) 2012-04-24

Similar Documents

Publication Publication Date Title
CN101589026B (zh) 治疗脑神经胶质瘤的方法
ES2266512T3 (es) Composiciones para inhibir angiogenesis.
CN101534826A (zh) 治疗与年龄相关的黄斑变性（amd）的方法
JPH0564125B2 (https=)
US11396510B2 (en) GABAA receptor ligand
US11052086B2 (en) 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
CN113329749B (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
CN109700799A (zh) 牛樟芝素及其微纳米颗粒在制备肿瘤免疫治疗药物中的应用
CN111803489B (zh) 含笑内酯及其衍生物在垂体腺瘤治疗中的应用
US20040048808A1 (en) Methods for inhibiting angiogenesis
EP4706653A2 (en) Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers
CN108066337B (zh) KB-R7943或Bepridil在制备治疗神经胶质瘤的药物中的应用
CN117338786A (zh) 一种治疗急性t淋巴细胞白血病及合并中枢神经系统白血病的联合用药物及其应用
EP4479047A1 (en) Drug combinations and methods of treating ovarian cancer
CN104622874B (zh) Ccr4拮抗剂在抑制癌生长及转移中的应用
CN109806263A (zh) 一种药物组合物及其制备方法和用途
CN101601669B (zh) 用于治疗肿瘤的联合用药物
POTTS Tracer studies on a transplantable hamster melanoma
CN108904510A (zh) 地塞米松用于抑制或治疗胰腺癌的用途
WO2019164010A1 (ja) 膀胱がん用抗腫瘍剤および膀胱がんの処置方法
CN101723906B (zh) 一种化合物、含该化合物的药物组合物及制备方法和用途
CN105078993B (zh) 一种吲唑类化合物组合物及其制备方法和应用
CN102389420A (zh) 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备防治肺纤维化药物中的应用
WO2025188783A1 (en) Therapeutic compositions and methods for treating cancers
CN118304286A (zh) 芥子碱硫氰酸盐在制备治疗视网膜新生血管相关疾病的药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131016

Termination date: 20200622